Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours. (POTENTIA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04839991
Recruitment Status : Recruiting
First Posted : April 9, 2021
Last Update Posted : June 10, 2021
Sponsor:
Information provided by (Responsible Party):
Crescendo Biologics Ltd.

Brief Summary:
FIH, Phase 1, open-label, multi centre study of CB307, a trispecific Humabody® T-cell enhancer, in patients with advanced and/or metastatic PSMA+ solid tumours to assess safety and torelability to determine MTD and RP2D.

Condition or disease Intervention/treatment Phase
Advanced and/or Metastatic Solid Tumours Drug: CB307 Phase 1

Detailed Description:
FIH, Phase 1, open-label, multi centre, non randomised study of CB307, a trispecific Humabody® T-cell enhancer, in patients with advanced and/or metastatic PSMA+ solid tumours. The study will consist of a dose escalation and cohort expansion. Up to 50 patients will participate. Patients will receive CB307 IV, until loss of clinical benefit, unacceptable toxicity or end of study. The dose escalation may be adapted by the SRC based on clinical experience and safety review.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Initial dose escalation cohorts followed by a single dose expansion cohort.
Masking: None (Open Label)
Masking Description: Open Label multi center non randomised study.
Primary Purpose: Treatment
Official Title: A Phase 1 Open-Label, Dose Escalation and Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of CB307, a Trispecific Humabody® T-cell Enhancer, in Patients With PSMA+ Advanced and/or Metastatic Solid Tumours
Actual Study Start Date : June 8, 2021
Estimated Primary Completion Date : July 25, 2023
Estimated Study Completion Date : September 25, 2023

Arm Intervention/treatment
Experimental: Multi center open label Dose Escalation followed by cohort expansion Drug: CB307
Tri-specific Humabody targeting CD137, prostate specific membrane antigen and human serum albumin




Primary Outcome Measures :
  1. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: The nature and frequency of any DLTs during the DLT-monitoring period assessed based on NCI CTCAE v5.0. up to 18 months duration. ]
    The objective of the study is to assess the safety and tolerability of the study drug CB307 and to determine the MTD (maximum tolerated dose)


Secondary Outcome Measures :
  1. To evaluate clinical efficacy measured as progression-free survival according to RECIST v.1.1 or PCWG3 [ Time Frame: Progression-free survival according to RECIST v1.1 or PCWG3 up to 18 months duration; and change from baseline in anti-drug (CB307) antibodies (ADA up to 18 months duration ]
    To measure how well the treatment succeeds in producing the desired effect.

  2. To measure how the body processes CB307 in the body over time [ Time Frame: PK parameters of CB307: data collected at time point 0 at each dosing period. Up to 18 months duration. ]
    To evaluate the pharmacokinetic trough levels before administration of CB307

  3. Pharmacokinetic of CB307 T1/2 [ Time Frame: Data collected up to 18 months duration. ]
    To evaluate the pharmacokinetic T1/2 after 3rd dose via IV for multiple dose levels of CB307

  4. Pharmacokinetic of CB307 Tmax [ Time Frame: Data collected up to 18 months duration. ]
    To evaluate the pharmacokinetic Tmax after 3rd dose via IV for multiple dose levels of CB307

  5. To measure Tumour Immune response [ Time Frame: Tumor response per RECIST ver 1.1 up to 18 months duration ]
    To determine the potential of CB307 to produce an immune response and assess the relationship with other outcome measures

  6. Relationship of CB307 to anti tumour response [ Time Frame: PSA response defined as a >50% decrease in PSA up to 18 months duration ]
    To evaluate the preliminary CB307 dose in relationship to activity of changes in tumour



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Capable of understanding the written informed consent.
  2. Aged at least 18 years
  3. Not amenable to standard of care.
  4. ECOG PS 0-1
  5. Has documented histologically confirmed diagnosis of PSMA+ advanced or metastatic solid tumours
  6. Has radiologically measurable disease per RECIST v1.1 or elevated serum PSA for castration resistant prostate cancer patients with only bone metastasis
  7. Adequate organ function

Exclusion Criteria:

  1. Subjects with autoimmune disease or regular immunosuppressants
  2. Has discontinued from anti-CTLA 4, anti-PD1 or anti-PD-L1 antibody because of intolerable toxicity
  3. Has brain metastasis including leptomeningeal metastasis or primary brain tumour.
  4. Has current or history of CNS disease
  5. Has known active infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04839991


Contacts
Layout table for location contacts
Contact: MD 01223497140 Clinicaltrials@crescendobiologics.com
Contact: S Rajbally 01223497140 SRajbally@crescendobiologics.com

Locations
Layout table for location information
United Kingdom
The Christie NHS Foundation Trust Not yet recruiting
Manchester, Greater Manchester, United Kingdom, M20 4BX
Contact: MD       fiona.thistlethwaite@christie.nhs.uk   
The Clatterbridge Cancer Centre NHS Foundation Trust Not yet recruiting
Bebington, Merseyside, United Kingdom, CH63 4JY
Contact: MD       isabel.syndikus@ccotrust.nhs.uk   
Royal Marsden Hospital Recruiting
London, Surrey, United Kingdom, SM2 5PT
Contact: MD       Johann.DeBono@icr.ac.uk   
University College London Hospitals NHS Foundation Trust Not yet recruiting
London, United Kingdom, NW1 2BU
Contact: MD       m.linch@nhs.net   
Sarah Cannon Research Institute, UK Recruiting
London, United Kingdom, W1G 6AD
Contact: MD       tobias.arkenau@hcahealthcare.co.uk   
Sponsors and Collaborators
Crescendo Biologics Ltd.
Investigators
Layout table for investigator information
Study Director: S Rajbally Crescendo Biiologics
Layout table for additonal information
Responsible Party: Crescendo Biologics Ltd.
ClinicalTrials.gov Identifier: NCT04839991    
Other Study ID Numbers: CBT307-1
2019-004584-46 ( EudraCT Number )
First Posted: April 9, 2021    Key Record Dates
Last Update Posted: June 10, 2021
Last Verified: April 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Crescendo Biologics Ltd.:
Prostate Specific Membrane Antigen (PSMA)
Solid Tumours
Castration-resistant prostate cancer (CRPC)
First in Human (FIH)
Phase 1 Study
CD137
4-1BB
Crescendo Biologics
CB307
Humabody
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms